Stock SLNO SOLENO THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Soleno Therapeutics, Inc.

Equities

SLNO

US8342033094

Real-time Estimate Cboe BZX
Other stock markets
 02:24:53 2024-04-30 pm EDT 		5-day change 1st Jan Change
44.92 USD -1.33% Intraday chart for Soleno Therapeutics, Inc. +13.53% +13.22%
Apr. 29 Soleno Therapeutics' Shares Jump After FDA Grants Breakthrough Designation for Prader-Willi Syndrome Treatment MT
Apr. 29 Soleno Therapeutics Gets Breakthrough Therapy Designation for Diazoxide Choline DJ

Evolution of the average Target Price on Soleno Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

b705ed07bbce1ec16bcef0829770eb.XaspbM-V9k-TwFNtIeFvwVt6GWDnx_zFJpSWRvAanQU.CeBDDrbtzy6iij85YokrnilLcVGIjJSxZabDdp5z63AP-WhYgNepLf74Hg~9a3b1985451f0b80dfa8fafff00999da

Analyst Recommendations on Soleno Therapeutics, Inc.

Soleno Therapeutics Insider Sold Shares Worth $784,645, According to a Recent SEC Filing MT
Piper Sandler Starts Soleno Therapeutics With Overweight Rating, $93 Price Target MT
Stifel Starts Soleno Therapeutics With Buy Rating, $63 Price Target MT
Oppenheimer Lifts Price Target on Soleno Therapeutics to $47 From $44, Maintains Outperform Rating MT
Oppenheimer Adjusts Soleno Therapeutics Price Target to $44 From $39, Maintains Outperform Rating MT
Wall St slides as rate concerns keep Treasury yields near 16-year peak RE
Cantor Fitzgerald Raises Price Target on Soleno Therapeutics to $35 From $19, Maintains Overweight Rating MT
Oppenheimer Raises Soleno Therapeutics Price Target to $14 Form $8, Maintains Outperform Rating MT
Cantor Fitzgerald Starts Soleno Therapeutics at Overweight With $19 Price Target MT
Oppenheimer Adjusts Soleno Therapeutics PT to $8 From $2 to Better Reflect Recent Reverse Stock Split, Maintains Outperform Rating MT
Oppenheimer Adjusts Soleno Therapeutics Price Target to $2 From $3, Maintains Outperform Rating MT
Oppenheimer Adjusts Soleno Therapeutics' Price Target to $3 From $5, Maintains Outperform Rating MT
History shows stocks can weather rate hike cycle RE
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
45.53 USD
Average target price
65.17 USD
Spread / Average Target
+43.13%
High Price Target
93 USD
Spread / Highest target
+104.26%
Low Price Target
51 USD
Spread / Lowest Target
+12.01%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Soleno Therapeutics, Inc.

Piper Sandler
Stifel Nicolaus
Oppenheimer
Cantor Fitzgerald

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. SLNO Stock
  4. Consensus Soleno Therapeutics, Inc.